Effect of date of drug marketing on disproportionality measures in pharmacovigilance: The example of suicide with SSRIs using data from the UK MHRA

Drug Safety

Volumn 32, Issue 5, 2009, Pages 441-447

  Pariente, Antoine ^a,b,c   Daveluy, Amélie ^b,c,d   Laribière Bénard, Anne ^b,d   Miremont Salame, Ghada ^a,b,d   Begaud, Bernard ^a,b,c   Moore, Nicholas ^a,b,c  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Centre de Pharmacovigilance Bordeaux   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH CARE; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SUICIDAL IDEATION; UNITED KINGDOM;

EID: 65949121637     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932050-00007     Document Type: Article

References (30)

1. Smith CC, Bennett PM, Pearce HM, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol 1996 Oct; 42 (4): 423-9
2. Rawlins MD. Spontaneous reporting of adverse drug reactions: I. The data. Br J Clin Pharmacol 1988 Jul; 26 (1): 1-5
3. Rawlins MD. Spontaneous reporting of adverse drug reactions: II. Uses. Br J Clin Pharmacol 1988 Jul; 26 (1): 7-11
4. van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 2002 Jan-Feb; 11 (1): 3-10
5. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004 Aug; 13 (8): 519-23
6. Moore N, Thiessard F, Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2005 Apr; 14 (4): 285-6
7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001 Oct-Nov; 10 (6): 483-6
8. Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997; 44 (5): 513-8
9. Mann RD. Assessments of disproportionality. Pharmacoepidemiol Drug Saf 2004 Aug; 13 (8): 501-2
10. Hennessy S. Disproportionality analyses of spontaneous reports. Pharmacoepidemiol Drug Saf 2004 Aug; 13 (8): 503-4
11. Almenoff JS, DuMouchel W, Kindman LA, et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf 2003 Sep; 12 (6): 517-21
12. Stricker BH, Psaty BM. Detection verification, and quantification of adverse drug reactions. BMJ 2004 Jul 3; 329 (7456): 44-7
13. Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ 1998; 317 (7151): 119-20
14. Eland IA, Belton KJ, van Grootheest AC, et al. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 1999 Oct; 48 (4): 623-7
15. Alvarez-Requejo A, Carvajal A, Begaud B, et al. Underreporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998 Aug; 54 (6): 483-8
16. Begaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France [letter]. JAMA 2002 Oct 2; 288 (13): 1588
17. Tubert-Bitter P, Haramburu F, Begaud B, et al. Spontaneous reporting of adverse drug reactions: who reports and what? Pharmacoepidemiol Drug Saf 1998 Sep; 7 (5): 323-9
18. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf 2001; 24 (3): 233-7
19. Haramburu F, Begaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol 1997 Sep; 44 (3): 299-301
20. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003 Jun; 12 (4): 271-81
21. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992 Feb 20; 326 (8): 501-6
22. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol 1996 Dec 15; 144 (12): 1161-9
23. Pierfitte C, Begaud B, Lagnaoui R, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999; 47 (3): 329-31
24. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30 (10): 891-8
25. Lebourges J. Complications of antidepressive treatments. Clinique (Paris) 1963 Oct 31; 58: 613-6
26. Poeldinger W. The drug therapy of depression with particular consideration of suicide prophylaxis. Schweiz Arch Neurol Neurochir Psychiatr 1966; 98 (2): 304-12
27. Anonymous. BBC Panorama: unprecedented public response to evidence of SSRI drug harm [online]. Available from URL: http://www.ahrp.org/infomail/0503/ 21.php [Accessed 2009 Mar 03]
28. Medawar C, HerxheimerA, Bell A, et al. Panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Saf Med 2002; 15: 161-9
29. Lagier G, Vincens M, Castot A. Imputability in drug monitoring: principles of the balanced drug reaction assessment method and principal errors to avoid. Therapie 1983 May-Jun; 38 (3): 303-18
30. Safety of Seroxat (paroxetine) in children and adolescents under 18 years: contraindication in the treatment of depressive illness. Epinet message from Professor G. Duff, Chairman of Committee on Safety of Medicines (CSM), 10 June 2003 [online]. Available from URL: http://www.mhra.gov.uk/ Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON2015704 [Accessed 2009 Mar 18]